Nutritional Growth Solutions (ASX:NGS) receives positive results from Healthy Heights clinical trial

• Nutritional Growth Solutions (NGS) receives positive results from its Healthy Heights Grow Daily Boys 10+ formula trial in boys 10 and over
• The aim of this trial was to assess the effect of Grow Daily Boys 10+ on height, weight and body composition in healthy, short and lean males aged between 10 to 14.5 years
• A six-month extension phase found significant dose-response correlation between growth in height, weight and muscle mass and the consumption of Grow Daily Boys 10+
• Participants who consumed at least 50 per cent of the recommended daily dose maintained their average height growth rate while those who consumed less than 50 per cent showed a decrease
• NGS has ended the day 8.14 per cent in the red to close at 7.9 cents

Nutritional Growth Solutions (NGS) has received positive results from its Healthy Heights Grow Daily Boys 10+ formula trial in boys aged 10 and over.

The trial aimed to assess the effect of Grow Daily Boys 10+ on height, weight and body composition in healthy, short and lean males aged between 10 to 14.5 years.

A six-month open-label extension phase was undertaken following a six-month double-blinded intervention phase where participants received nutritional formula or placebo.

This extension phase found significant dose-response correlation between growth in height, weight and muscle mass and the consumption of Grow Daily Boys 10+.

Participants who consumed at least 50 per cent of the recommended daily dose for either six or 12 months maintained their average height growth rate while those who consumed less than 50 per cent showed a decrease in growth rate.

Additionally, changes in fat mass and fat mass percentage were minimal, less than 800 grams and 0.8 per cent, respectively, showing there were no obesogenic effects.

“Assessment of the impact of nutritional support in older children and adolescents has historically been challenging, due to differences in puberty timing and the tempo of change,” NGS Director of Clinical Studies and Lead Researcher Dr Michal Yackobovitch-Gavan said.

“However, the strength of this study lies in its one-year, two-phase design, comprising six months of a double-blinded intervention, followed by an additional six months of an open-label extension, the relatively large sample size, the long duration, and the evaluation of body composition.

The company said that both phases showed it that an intervention with a multi-nutrient, protein-rich formula could effectively improve the gain in height, weight, fat-free-mass and muscle mass, in short and lean males between 10 and 14.

NGS has ended the day 8.14 per cent in the red to close at 7.9 cents.